ACRGF:OTC-Acreage Holdings, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 5.56

Change

0.00 (0.00)%

Market Cap

USD 0.36B

Volume

0.36M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

+4.29 (+4.45%)

USD40.69B 18.59 N/A
TKPHF Takeda Pharmaceutical Company ..

+1.87 (+6.32%)

USD37.93B 16.50 N/A
ESALF Eisai Co., Ltd

N/A

USD17.33B 30.27 N/A
SGIOY Shionogi & Co., Ltd

+0.36 (+3.12%)

USD14.58B 1.75 N/A
SFOSF Shanghai Fosun Pharmaceutical ..

-0.17 (-5.11%)

USD11.67B 19.59 N/A
MTZPY Mitsubishi Tanabe Pharma Corpo..

+0.01 (+0.06%)

USD9.14B 18.95 N/A
TEVJF Teva Pharmaceutical Industries..

-0.75 (-9.09%)

USD8.32B 483.60 8.03
STDAF STADA Arzneimittel Aktiengesel..

N/A

USD5.82B 16.00 N/A
HLUYY H. Lundbeck A/S

-0.03 (-0.10%)

USD5.72B 9.38 N/A
HLUKF H. Lundbeck A/S

-0.59 (-2.05%)

USD5.63B 9.10 N/A

ETFs Containing ACRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.87% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.87% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -73.27% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.27% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.11% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.11% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.92% N/A N/A N/A N/A
Risk Adjusted Return -44.99% N/A N/A N/A N/A
Market Capitalization 0.36B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.78 N/A N/A N/A N/A
Price / Cash Flow Ratio -10.14 N/A N/A N/A N/A
EV/EBITDA -3.00 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -86.02% N/A N/A N/A N/A
Return on Invested Capital -32.71% N/A N/A N/A N/A
Return on Assets -20.74% N/A N/A N/A N/A
Debt to Equity Ratio 0.13% N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 258.06 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.